KORU Medical 2025 Q2 Earnings Surpasses $10M Revenue, Narrows Net Loss

KORU Medical (KRMD) reported its fiscal 2025 Q2 earnings on August 6th, 2025. The company demonstrated strong performance by surpassing $10 million in revenue for the first time and achieving its sixth consecutive quarter of double-digit growth. It also raised its full-year 2025 revenue guidance and delivered positive adjusted EBITDA.

Revenue
KORU Medical's total revenue increased by 20.9% to $10.19 million in 2025 Q2, up from $8.43 million in 2024 Q2. Domestic core revenues rose 15.3% to $7.1 million, driven by higher consumable volumes from new patient starts and market share gains. International core revenues surged 33.9% to $2.2 million, fueled by prefill patient conversions, new patient starts, and expansion into new geographic markets. Pharma Services and Clinical Trials net revenues grew 42.1% to $0.9 million, attributed to higher product sales for clinical trials.

Earnings/Net Income
KORU Medical maintained stable EPS at $0.00 in 2025 Q2 compared to the prior year. The company narrowed its net loss to $206,867 in 2025 Q2, a 79.1% reduction from the $988,715 net loss in 2024 Q2. This improvement reflects disciplined execution and improved gross profit, though the net loss remains a challenge as it continues to impact earnings.

Price Action
The stock price of KORU Medical edged down 0.31% during the latest trading day, dropped 6.59% during the most recent full trading week, and tumbled 11.17% month-to-date.

Post-Earnings Price Action Review
The strategy of buying KRMD shares after a revenue raise quarter-over-quarter on the financial report release date and holding for 30 days delivered moderate returns over the past three years. The compound annual growth rate was 14.03%, trailing the benchmark by 1.73 percentage points. The strategy had a maximum drawdown of 0.00%, a Sharpe ratio of 0.24, and a volatility of 58.60%.

CEO Commentary
Linda Tharby, President and CEO of KORU Medical, highlighted the company’s record-breaking performance, including surpassing $10 million in revenue for the first time and achieving six consecutive quarters of double-digit growth. She emphasized strong execution in gaining global market share in the SCIg space, advancing international expansion, and submitting a 510(k) filing to add a new drug to the Freedom Infusion System. The CEO noted the company’s operational success in delivering positive adjusted EBITDA, driven by disciplined execution and focused capital allocation, while continuing to invest in strategic growth areas. She expressed optimism about KORU Medical’s ability to drive shareholder value through continued scaling and market expansion.

Guidance
KORU Medical raised its full-year 2025 revenue guidance to $39.5 - $40.5 million, representing growth of 18% - 20%, from the prior range of $38.5 - $39.5 million. The company reiterated its full-year 2025 gross margin guidance of 61% - 63% and expects positive cash flow from operations for the full year 2025, with an ending cash balance greater than $8.1 million.

Additional News
KORU Medical Systems announced several business highlights following the Q2 2025 earnings release. Adam Kalbermatten joined the company as Chief Commercial Officer, bringing 20 years of experience in drug delivery partnerships across the pharma and biotech sectors. This appointment aims to strengthen the company’s commercial capabilities and expand its market reach. Additionally, the Freedom Infusion System™ received expanded indications for use with Empaveli® in the treatment of C3G and Primary IC-MPGN. This development broadens the therapeutic applications of the Freedom Infusion System and positions the company to serve a wider patient population. Another significant update was the submission for FDA 510(k) clearance for a commercialized rare disease biologic drug with the Freedom Infusion System. This filing represents a critical step in expanding the company’s product portfolio and entering new therapeutic areas. These strategic initiatives underscore KORU Medical’s commitment to innovation and growth.